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was	 the	maximum	 serum	 cortisol	 concentration	 up	 to	 240	minutes	 after	 Infacort® 
	administration.	Secondary	end-	points	were	palatability	and	adverse	events	(AEs).
Results:	 All	 children	 showed	 an	 increase	 in	 cortisol	 above	 baseline	 after	 Infacort® 





Conclusions:	 Infacort®	 is	well	tolerated,	easy	to	administer	to	neonates,	 infants	and	
children	and	shows	good	absorption,	with	cortisol	levels	at	60	minutes	after	adminis-
tration	similar	to	physiological	cortisol	levels	in	healthy	children.










replacement	 from	 birth	 to	 end	 of	 life.1	 The	 recommended	 replace-
ment	 therapy	 is	 hydrocortisone,2,3	 but	 there	 are	 no	 licensed	 dose-	
appropriate	 formulations	 of	 hydrocortisone	 for	 children.	 Children	
rely	either	on	parents	crushing	 tablets	or	pharmacists	 compounding	









tance	 criteria	 for	precision	of	mass	 and/or	 content,5	 and	difficulties	









Hydrocortisone	as	 replacement	 therapy	 in	AI	has	a	narrow	ther-
apeutic	 index,	and	patients	with	CAH	have	poor	health	outcomes	in	
adulthood,	which	are	 in	part	 related	 to	 treatment	 in	 childhood.7,8	A	
recent	 survey	of	paediatric	 endocrinologists	 across	16	 countries	 re-
vealed	wide	heterogeneity	in	the	hydrocortisone	formulations	used	to	


















A	 Phase	 1	 study	 of	 Infacort®	 demonstrated	 good	 tolerability	 and	












2  | SUBJECTS AND METHODS
2.1 | Trial design
This	was	a	Phase	3,	open-	label,	single-	dose	study	conducted	at	a	sin-
gle	 centre;	Charité-	Universitätsmedizin,	 Berlin,	Germany.	 The	 study	
F IGURE  1  Illustration	of	Infacort® 
formulation	and	its	administration
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enrolled	 subjects	 into	 three	 consecutive	 cohorts:	 Cohort	 1,	 chil-
dren	(aged	2	to	<6	years,	n	=	12);	Cohort	2,	infants	(aged	28	days	to	
<2	years,	n	=	6);	and	Cohort	3,	neonates	(aged	1	to	<28	days,	n	=	6).	
Neonatal	 participants	 were	 also	 recruited	 at	 remote	 sites	 but	 had	
their	care	transferred	to	the	central	site	for	the	duration	of	the	study	













complied	with	 the	 ethical	 principles	 of	 the	Declaration	 of	 Helsinki,	
International	 Council	 for	 Harmonisation	 (ICH)	 and	 Good	 Clinical	






Comprised	 adequately	 hydrated	 and	 nourished	 children	 (male	 or	




had	 clinical	 signs	 of	 acute	 infection	 or	 fever	 on	Day	 1;	were	 un-
able	to	take	oral	medications;	were	receiving	concomitant	therapy	
(other	 than	 for	AI,	 vitamin	D,	 fluoride,	 thyroxine	and	growth	hor-






doses	 of	 immediate-	release	 multiparticulate	 granules	 (Figure	1).	
All	 participants	were	given	a	 single	dose	of	 Infacort®	 at	 study	Visit	
2	 that	was	equivalent	 to	 their	 routine	hydrocortisone	dose	 (Cohort	 
1:	4.01	±	0.8	mg/m2	body	surface	area	(BSA),	Cohort	2:	4.98	±	0.8	mg/m2 




to	 delay	 hydrocortisone	 absorption	 and	 prolong	 response,13	 dosing	
took	place	 at	 least	 2	hours	 after	 food	 in	 children	 aged	≥1	year	 and	
45	minutes	 in	children	aged	<1	year	and	at	 least	8	hours	after	 their	
last	dose	of	hydrocortisone.	Participants	did	not	eat	after	 Infacort® 
administration	 for	60	minutes	 in	 children	 aged	≥1	year	 and	30	min-






The	 primary	 end-	point	 of	 this	 study	was	maximum	 serum	 cortisol	
concentration	 up	 to	 240	minutes	 after	 Infacort®	 administration	
using	samples	taken	at	0,	60	and	240	minutes	postdose.	Secondary	
end-	points	included	palatability	of	Infacort®,	AEs	and	vital	signs	re-









immunoassay	 method	 (Elecsys	 Cortisol,	 Roche	 Diagnostics).	 In	
the	protocol,	it	was	stated	that	if	the	Investigator	judged	the	par-
ticipant	 needed	 supplementary	 hydrocortisone	 after	 Infacort® 
administration	and/or	 the	60-	minute	 safety	 cortisol	 assessment	
result	was	<100	nmol	L−1,	an	additional	cortisol	sample	would	be	
taken,	 and	 emergency	 hydrocortisone	 would	 be	 administered;	
however,	 this	 action	was	not	 taken	during	 the	 trial.	 Serum	cor-
tisol	 levels	were	measured	using	previously	 reported,	validated,	
liquid	chromatography-	mass	spectrometry	at	the	central	 labora-
tory	 (Simbec	 Research	 Ltd,	 Merthyr	 Tydfil,	 UK)9;	 only	 baseline	
and	 the	 60-	minute	 safety	 cortisol	 samples	 were	 additionally	
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2.7 | Statistical methods
Pharmacokinetic	 (PK)	 data	 from	 two	Phase	 1	 studies	 (ClinicalTrials.
gov	Reference	No.	NCT02777268	&	NCT01960530)	of	Infacort® in 
healthy	adult	volunteers9	were	used	to	derive	and	minimize	the	popu-























ministration	 vs	baseline.	Cortisol	 levels	were	 also	 categorized	using	










Characteristic Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
Mean	(SD)	age,	weeks 171.7	(49.2) 63.9	(30.8) 3.2	(0.5) 102.6	(82.6)
Median	(range)	age,	weeks 171.0	(106.3,	244.0) 70.9	(17.7,	94.9) 3.3	(2.3,	3.7) 100.6	(2.3,	244)
Male,	% 7	(58.3) 4	(66.7) 2	(33.3) 13	(54.2)
Ethnic	origin
White,	n	(%) 12	(100) 6	(100) 6	(100) 24	(100)
Mean	(SD)	body	mass	index	(kg/m2) 17.4	(1.7) 17.7	(1.5) 12.7	(1.8) 16.3	(2.6)
Median	(ranges)	body	mass	index	(kg/m²) 17.4	(14.6,	20.6) 17.3	(16.4,	20.5) 12.3	(11.0,	15.1) 16.6	(11.0,	20.6)
Mean	body	mass	index	SDS	(SD) 1.02	(1.0) 0.71	(0.9) a
Median	(ranges)	body	mass	index	SDS 0.96	(−0.7,	2.1) −0.31	(−1.3,	2.0) a 0.06	(−1.3,	2.1)
Mean	(SD)	body	surface	area	(m2) 0.64	(0.08) 0.44	(0.08) 0.22	(0.03) 0.49	(0.19)
Median	(ranges)	body	surface	area	(m²) 0.64	(0.5,	0.8) 0.49	(0.3,	0.5) 0.22	(0.2,	0.3) 0.51	(0.2,	0.8)
Concomitant	medications
n	(%) 12	(100) 6	(100) 6	(100) 24	(100)
Vitamins 0 1	(16.7) 4	(66.7) 5	(20.8)
Fludrocortisone 12	(100) 5	(83.3) 6	(100) 23	(95.8)
Thyroxine 0 1	(16.7) 0 1	(4.2)
Concurrent	conditions
n	(%)
Virilismb 1	(8.3) 0 4	(66.7) 5	(20.8)
Hypothyroidism 0 1	(16.7) 0 1	(4.2)
Rhinitis 0 1	(16.7) 0 1	(4.2)
Skin	infection 1	(8.3) 0 0 1	(4.2)
Renal	hypoplasia 0 0 1	(16.7) 1	(4.2)
Atopic	dermatitis 1	(8.3) 0 0 1	(4.2)
aBMI-	SDS	not	calculable	due	to	missing	reference	data	in	newborns.
bVirilisation	of	the	female	genitalia	according	Prader	stage	II-	IV.




Median	 participant	 age	 was	 3	years	 and	 3	months	 and	 54.2%	 were	
male;	all	subjects	were	white.	All	subjects	were	successfully	dosed.
3.2 | Hydrocortisone absorption
The	 primary	 end-	point	 of	 the	 study	 was	 met	 as	 shown	 in	 Figure	2.	
Increases	 from	 baseline	 in	 cortisol	 Cmax	 up	 to	 240	minutes	 after	
Infacort®	 administration	were	statistically	 significant	 for	 the	combined	
study	cohorts	 (P <	.0001).	A	relevant	 increase	from	baseline	 in	cortisol	




−1	 for	 the	overall	population	 (Cohort	
1:	 547.1	±	82.9	nmol	L−1;	 Cohort	 2:	 450.1	±	88.9	nmol	L−1;	 Cohort	 3:	
815.7	±	474.9	nmol	L−1).	 A	 summary	 of	 the	 primary	 efficacy	 analysis	
across	 all	 study	 cohorts	 and	 the	 geometric	mean	 serum	 cortisol	 con-
centrations	 at	 baseline	 and	 after	 Infacort®	 administration	 is	 shown	 in	
Table	2.	 Results	 of	 the	 primary	 analysis	were	 confirmed	 in	 a	 second-
ary	analysis	using	the	paired	t	 test.	The	ratios	of	geometric	means	for	
the	comparison	of	cortisol	concentration	at	Cmax	(60	minutes)/baseline	
were	 statistically	 significant	 overall	 (2535.0	 [95%	CI	 1792.4,	 3585.3];	
P	<	.0001)	and	for	each	cohort	 (P <	.0001,	P =	.0007	and	P	<	.0001	for	










Infacort®	 was	 positively	 assessed	 in	 terms	 of	 palatability.	 Among	
parents	and	carers	asked	about	their	child’s	experience	of	taking	the	
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up	 to	 6	years	with	 AI	was	well	 tolerated	 and	 provided	 appropriate	
exposure	to	cortisol.	The	mean	cortisol	level	in	the	children	after	tak-
ing	their	standard	hydrocortisone	dose	as	Infacort®	was	626	nmol	L−1,	
very	 similar	 to	 the	 mean	 peak	 concentrations	 of	 cortisol	 seen	 in	
healthy	paediatric	subjects	in	the	early	morning	of	691	nmol	L−1.14	All	
the	children	had	a	cortisol	concentration	at	60	mins	≥150	nmol	L−1,	


















Parameter Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
N	(%)	patients	with	cortisol	levels	significantly	above	baseline	at:
Cmax 12	(100.0)* 6	(100.0)** 6	(100.0)** 24	(100.0)***
60	min 12	(100.0)* 6	(100.0)** 6	(100.0)** 24	(100.0)***






























Significance	of	levels	above	baseline:	*P =	.0005;	**P =	.0313;	***P	<	.0001;	****P =	.0026.
TABLE  3 Responses	to	palatability	questionnaire	among	children	in	Cohort	1
Question No. of responses
No. of events (%)
1 Very good 2 3 Not good/not bad 4 5 Very bad
Q1.	How	did	the	medicine	smell? 6 1	(16.7) 0 4	(66.7) 0 1	(16.7)
Q2.	What	was	it	like	to	swallow	the	medicine 6 3	(50.0) 0 1	(16.7) 0 2	(33.3)
Q3.	What	did	the	medicine	taste	like 6 3	(50.0) 0 3	(50.0) 0 0
Q4.	How	did	the	medicine	feel	in	your	mouth 6 3	(50.0) 0 1	(16.7) 2	(33.3) 0
Q5.	Would	you	take	this	medicine	again? 6 4	(66.7) 0 1	(16.7) 0 1	(16.7)





and	hydrocortisone	 tablet	 given	 to	 adults	of	566	and	598	nmol	L−1,	
respectively.9	Thus,	it	appears	the	absorption	of	Infacort®	was	similar	
in	very	young	children	to	that	seen	in	adults.
By	 240	minutes	 after	 Infacort,	 cortisol	 concentrations	 for	 all	
three	cohorts	had	dropped	to	<100	nmol	L−1	 in	the	majority	of	chil-
dren,	although	still	above	baseline	in	most	children.	These	results	are	
similar	 to	 those	 found	 in	healthy	dexamethasone-	suppressed	volun-
teers	 given	hydrocortisone	5	mg	where	 the	mean	±	SD	 cortisol	was	
86	±	21	nmol	L−1.9	These	 results	also	 reflect	 the	previous	 reports	of	

















Drug	dosing	 in	neonates	 is	 challenging	due	 to	 significant	differ-
ences	 in	 drug	 absorption,	 distribution,	 metabolism	 and	 elimination	
compared	to	older	children	and	adults.	Most	drugs	given	to	neonates	
are	 insufficiently	 studied.19	 Neonates	 are	 extremely	 vulnerable	 to	












as	 compounded	 hydrocortisone	 is	 often	 mixed	 with	 a	 sweetener,	
following	 methods	 used	 worldwide,	 such	 as	 Ora-	sweet®	 (Perrigo	
Company,	Allegan,	Michigan,	USA),	which	contains	sucrose,	and	so	
could	have	led	to	a	nonsweet	formulation	being	poorly	received.25,26 
Sweetening	of	paediatric	 formulations	 in	 this	way,	 to	 improve	pal-





sure	 to	 Infacort®	 and	during	 the	 study	visit;	 therefore,	 it	does	not	
reflect	continuous	daily	experience	with	the	drug.
This	 study	 highlights	 the	 challenges	 in	 developing	 medications	
for	neonates,	infants	and	children	and	demonstrates	that	with	careful	
consideration	these	can	be	overcome.	To	address	concerns	regarding	
testing	 in	 neonates,	we	 used	 three	 cohorts	 of	 descending	 age	 only	
progressing	to	test	neonates	in	Cohort	3	after	safety	had	been	estab-
lished	 in	 the	older	cohorts	and	safety	confirmed	by	an	 Independent	
TABLE  4 Summary	of	TEAEs	and	by	system	organ	class	and	preferred	term
Safety parameter Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
No.	of	events/subjects	(%	of	subjects	in	cohort)
TEAEs 7/4	(33) 2/2	(33) 3/2	(33) 12/8	(33)
Serious	TEAEs 0 0 0 0
TEAE	intensity
Mild 5/3	(25) 2/2	(33) 3/2	(33) 10/7	(29)
Moderate 2/1	(8) 0 0 2/1	(4)
Severe 0 0 0 0
Gastrointestinal	disorder 3/3	(25) 1/1	(17) 3/2	(33) 7/6	(25)
Diarrhoea 2/2	(17) 1/1	(17) 0 3/3	(13)
Vomiting 1/1	(8) 0 1/1	(17) 2/2	(8)
Spitting	up 0 0 2/1	(17) 2/1	(4)
Skin	and	subcutaneous	disorders 3/2	(17) 1/1	(17) 0 2/2	(8)
Rash 1/1	(8) 0 0 2/1	(4)
Hyperhidrosis 2/1	(8) 0 0 1/1	(4)
General	disorders	and	administration	site	conditions
Fatigue 1/1	(8) 0 0 1/1	(4)
TEAE,	treatment-	emergent	adverse	event.

























is	 well	 tolerated,	 easy	 to	 administer	 to	 neonates,	 infants	 and	 chil-
dren,	and	shows	good	absorption,	with	cortisol	 levels	at	60	minutes	
after	administration	similar	to	physiological	cortisol	 levels	 in	healthy	
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